JHSM
Journal of Health Sciences and Medicine

Journal of Health Sciences and Medicine (JHSM) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

ISSN: Active
eISSN: 2636-8579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
Correlation between antibody levels and long-term symptoms in survivors of COVID-19: health outcomes and societal implications
Abstract
Aims: It was aimed to evaluate the relationship between antibody levels, demographic characteristics, and ongoing symptoms of people who have positive COVID-19 real-time PCR (RT-PCR) tests and donated plasma after the disease.
Methods: Patients who voluntarily donated plasma were called by phone, and 105 patients who wanted to participate in the survey were included in the study. Ongoing symptoms, antibody test results, demographic characteristics, and other data of the participants were recorded.
Results: IgM was high in patients whose first complaint was fever and muscle pain at the onset of the disease and who used favipiravir for treatment (p=0.030, p=0.035, p=0.007). In those who survived the disease, it was determined that the IgM level decreased after the peak in the first month and the IgG level in the third month; the results were statistically significant. The IgG level decreased with the elapsed time and smoking, and the IgG level was found to be high in those who used favipiravir, hydroxychloroquine, or both during the disease and those in the AB blood type.
Conclusion: Some symptoms may persist even after the COVID-19 infection has been overcome. This study will contribute to a better understanding of this disease and the process after it.

Keywords : COVID-19, IgM and IgG antibodies, post-COVID symptoms, cigarette, blood type

Download Article


1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of criticallyill patients with SARS-CoV-2 pneumonia in Wuhan, China: asingle-centered, retrospective, observational study. Lancet RespirMed. 2020;8(5):475-481.
2. Lovato A, de Filippis C, Marioni G. Upper airway symptomsin coronavirus disease 2019 (COVID-19). Am J Otolaryngol.2020;41(3):102474.
3. Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia:a review based on up-to-date knowledge. Am J Otolaryngol.2020;41(5):102581.
4. Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology ofCOVID-19. J Alzheimer's Dis. 2020; 76(1):3-19.
5. Dziedzic A, Wojtyczka R. The impact of coronavirus infectiousdisease 19 (COVID-19) on oral health. Oral Dis. 2021;27(Suppl3):703-706.
6. Freni F, Meduri A, Gazia F, et al. Symptomatology in head and neckdistrict in coronavirus disease (COVID-19): a possible neuroinvasiveaction of SARS-CoV-2. Am J Otolaryngol. 2020;41(5):102612.
7. Paranjpe I, Russak AJ, De Freitas JK, et al. Clinical characteristicsof hospitalized COVID-19 patients in New York City. MedRxiv.2020-04.
8. Zhu J, Zhong Z, Ji P, et al. Clinicopathological characteristics of8697 patients with COVID-19 in China: a meta-analysis. FamMed Commun Health. 2020;8(2):e000406.
9. Stowell S, Guarner J. Role of serology in the COVID-19 pandemic.Clin Infect. 2020;71(8):1935-1936 doi. org/10.1093/cid/ciaa510
10. Goërtz YM, Van Herck M, Delbressine JM, et al. Persistentsymptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4).00542.
11. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M.Projecting the transmission dynamics of SARS-CoV-2 throughthe postpandemic period. Science. 2020;368(6493):860-868.
12. Yang Z, Wang S, Li Q, et al. Determining SARS sub-clinicalinfection: a longitudinal seroepidemiological study in recoveredSARS patients and controls after an outbreak in a general hospital.Scandinav J Infect Dis. 2009;41(6-7):507-510.
13. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients afteracute COVID-19. JAMA. 2020;324(6):603-605.
14. Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistentsymptoms and health-related quality of life after hospitalizationfor COVID-19. J Infect. 2020;81(6):e4-e6.
15. Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association betweenABO blood groups and risk of SARS-CoV-2 pneumonia. Brit JHaematol. 2020;190(1):24.
16. Göker H, Karakulak EA, Demiroğlu H, et al. The effects of bloodgroup types on the risk of COVID-19 infection and its clinicaloutcome. Turk J Med Sci. 2020;50(4):679-683.
17. Jimenez-Ruiz CA, Lopez-Padilla D, Alonso-Arroyo A, Aleixandre-Benavent R, Solano-Reina S, de Granda-Orive JI. COVID-19 andsmoking: a systematic review and meta-analysis of the evidence.Archivos de Bronconeumol. 2020;57:21-34.
18. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: Thereality and challenges. J Microbiol Immunol Infect. 2020;53(3):436-443.
19. Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety offavipiravir, an oral RNA-dependent RNA polymerase inhibitor,in mild-to-moderate COVID-19: A randomized, comparative,open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103: 62-71.
20. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxicderivative of chloroquine, is effective in inhibiting SARS-CoV-2infection in vitro. Cell Discovery. 2020;6(1):16.
Article available in :
Volume 7, Issue 1, 2024
Page : 17-23
https://doi.org/10.32322/jhsm.1362907
Article Information
Received : 19 Eyl 2023
Accepted : 07 Kas 2023
Published : 15 Oca 2024
Corresponding Author :

Erdoğan Öz: Department of Family Medicine, Prof Dr Cemil Taşçıoğlu City Hospital, İstanbul, Turkiye

[email protected]
Citation : Vural A, Öz E, Küçükkelepçe O, Aslan Vural B, Sayıner HS. Correlation between antibody levels and long-term symptoms in survivors of COVID-19: health outcomes and societal implications. J Health Sci Med. 2024;7(1):17-23.

Read: 99
Cited: 0
Download : 105
_Footer